SHR3680
Not Tagged
['cspc']
dingwei ye presents data on shr3680 - a new ar antagonist - compared with bicalutamide with adt for mcspc. clear pfs and os benefit for this new agent - clearly leaving bicalutamide in the dust! #asco22 
Prostate cancer medical oncologist and physician-scientist, Kendrick Family Chair for Prostate Cancer Research, Cleveland Clinic. Posts are my own.